NASDAQ$XWEL

XpresSpa Group Inc · Q4 2023 earnings

Q4 2023 earnings · · Investor relations

Briefing

Reported fiscal year 2023 results, focusing on revenue growth and strategic expansion.

XWELL, Inc. reported fiscal year 2023 results, highlighting revenue of $30.1 million, driven by XpresSpa, Treat locations, and XpresTest. The company is focused on expanding wellness services, growing internationally, and extending its reach beyond airports.

  • Total revenue for fiscal year 2023 was $30.1 million.
  • Non-cash goodwill and intangible asset impairment charges totaled approximately $8.9 million.
  • The company is expanding its wellness portfolio, including new locations for Naples Wax Center.
  • XWELL is focused on improving operating performance and achieving profitability.

Headline financials

Total Revenue

$7.4M

Previous: $7.56M-2.1%
EPS (adj)

-$1.57

Previous: -$3.00+47.7%
Total operating expenses

$31.9M

No prior period
General and administrative

$13M

No prior period
Capital Expenditures

-$266K

Previous: $667K-139.9%
Net Income

-$28M

Previous: -$32.8M+14.6%
Operating Income

-$28.2M

Previous: -$31.2M+9.6%
Gross Profit

$583K

Previous: $410K+42.2%
Stock-Based Comp

$487K

Previous: $424K+14.9%

Revenue & EPS history

XpresSpa · Revenue · Quarterly

$7.4M

Q4 2023-2.1%vs Q4 2022
Beat estimate in 3 of 10 quarters(30%)
ActualEstimate

Revenue by segment

XpresSpa · $6.64M total across 3 segments · Q1 2026

  • XpresSpa
    $4.2M
  • XpresTest
    $1.92M
  • Naples Wax
    $524K

Forward guidance

XWELL remains committed to improving operating performance, reaching profitability, and delivering long-term strategic priorities, including expanding its wellness portfolio and extending its reach across transportation hubs.

Tailwinds

  • Expanding wellness portfolio with additional expansion into transportation hubs.
  • Launching TreatStudios, a new platform for independent wellness providers.
  • Opening a new XpresSpa location in Penn Station.
  • Opening additional Naples Wax Center locations in 2024.
  • Expanding the CDC's Traveler-based Genomic Surveillance program to test for more pathogens.

Headwinds

  • Unaudited financial statements for Q3 2023 should no longer be relied upon due to misapplication of GAAP.
  • Prior reports, press releases, earnings releases, and investor presentations covering Q3 2023 should no longer be relied upon.
  • Goodwill and intangible asset impairment charges totaling approximately $8.9 million.
  • Operating loss for 2023 was approximately $28.2 million.
  • Net loss attributable to XWELL was approximately $28.0 million for 2023.

Historical earnings impact

How earnings announcements have historically affected this stock's price.

Avg. return before/after earnings

Based on 19 quarterly earnings reports · overlaid with Q4 2023

Historical avgQ4 2023

+1.1%

Avg return

Earnings day

-2.3%

Avg return

5 days after

-4.5%

Avg return

30 days after

43%

16 / 37 earnings

Positive

+24.4%

Q4 2019

Best reaction

-11.1%

Q4 2017

Worst reaction

Earnings price reactions
QuarterReport dateReaction (Day 0)+5 days+30 days
Q1 2026
Q3 2025+0.0%-8.4%-9.6%
Q2 2025-5.8%-8.3%-8.3%
Q1 2025+1.2%+12.8%+9.3%
Q4 2024+0.0%+0.0%+15.4%
Q3 2024-1.2%-10.6%-24.1%
Q2 2024+3.7%+0.5%-14.8%
Q1 2024+3.4%-8.4%+41.6%
Q4 2023+0.0%+0.7%+32.1%
Q3 2023+6.2%+35.4%+31.1%
Q2 2023-4.2%-4.2%-25.0%
Q1 2023+0.0%+4.2%+4.2%
Q4 2022+6.3%-9.4%-21.9%
Q3 2022+0.0%-12.3%-10.5%
Q2 2022-6.5%-5.4%+9.7%
Q1 2022-1.1%-18.7%-22.0%
Q4 2021+8.2%+52.0%+11.2%
Q3 2021+11.7%+13.1%+25.5%
Q2 2021-6.9%-13.1%-2.9%
Q4 2020+6.4%-3.5%-20.8%
Q3 2020-1.1%-13.4%-22.5%
Q2 2020-6.5%-4.2%-42.9%
Q1 2020-7.5%-5.5%+6.5%
Q4 2019+24.4%+26.8%+17.1%
Q3 2019+2.0%-5.9%-41.6%
Q2 2019+0.0%+21.2%+31.9%
Q1 2019+7.8%-9.0%-40.0%
Q4 2018+0.3%-12.0%-22.7%
Q3 2018+0.0%+0.0%+11.1%
Q2 2018+0.0%-25.0%-20.0%
Q1 2018-4.8%-31.7%-20.6%
Q4 2017-11.1%-24.7%-17.3%
Q3 2017-0.8%-4.0%-6.5%
Q2 2017+11.5%+4.4%+9.7%
Q1 2017+4.9%+1.9%+5.6%
Q4 2016+0.9%-9.7%-20.8%
Q3 2016+0.8%-8.0%-15.6%
Q2 2016-1.9%-1.0%+1.9%
Q1 2016
Q4 2015
Q3 2015
Q2 2015
Q1 2015
Q4 2014
Q3 2014
Q2 2014
Q1 2014
Q4 2013
Q3 2013
Q2 2013
Q1 2013
Q4 2012
Q3 2012
Q2 2012
Q1 2012
Q4 2011
Q3 2011

Discussion

Share your read of this quarter. Sign-in carries your eToro identity.

Join the conversation

Sign in with eToro to post your read of this quarter and vote on others'.

Sign in with eToro